Swiss CDMO Sigfried has been on a growth jag over the last decade. | Siegfried has signed agreements to acquire the controlled drug substance businesses of the Noramco Group and Extractas Bioscience.

Affiliates of funds advised by SK Capital Partners, LP ("SK Capital"), a private investment firm focused on the life sciences, specialty materials, and ingredients sectors announced today they have ...

Key Insights Significant control over Siegfried Holding by retail investors implies that the general public has ...

Shares in Swiss contract-drug manufacturer Siegfried Holding climbed after the company said it struck agreements to buy sites in the U.S., expanding its footprint in the world's largest pharmaceutical ...

Siegfried, a global CDMO for the pharmaceutical industry, has signed binding agreements with an affiliate of SK Capital ...